CA
NZ
UK
AU
IND
US
Encore Capital Group, Inc. filed a Form 8-K with the SEC on August 19, 2026, disclosing the appointment of Robert Beck as a new independent director and the expansion of the Board of Directors from 8 to 9 members.
BKV Corporation filed a Form 10-K/A (Amendment No. 1) on August 19, 2026, amending its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, originally filed with the SEC on March 6, 2026, to correct auditor consent language, recast financial …
Kimball Electronics, Inc. filed its Form 10-K annual report with the U.S. Securities and Exchange Commission for the fiscal year ended June 30, 2026, disclosing financial and operational details including a subsequent-event acquisition and share data as of August 6, 2026.
Richtech Robotics Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 19, 2026, covering the fiscal quarter ended June 30, 2026.
A Form 4 filed on August 19, 2026 reports that Michael W. Collins, Chief Executive Officer of Bank of N.T. Butterfield & Son Ltd (NYSE:NTB), sold a total of 207,037 ordinary shares across three consecutive trading days ending August 19, 2026, reducing his direct …
Director Stephen T. Zarrilli filed a Form 4 with the SEC on August 19, 2026, reporting the exercise of stock options and a same-day sale of Class A Common Stock in Globus Medical Inc on August 18, 2026.
Julie Smolyansky, CEO, President, Secretary, and a director and 10% owner of Lifeway Foods, Inc. (NASDAQ:LWAY), filed a Form 4 on August 19, 2026, disclosing an open-market purchase of 2,000 shares of common stock on that same date.
Akash Khurana, Executive Vice President and Chief Information and Digital Officer of WESCO International Inc, filed a Form 4 on August 18, 2026, disclosing the sale of 3,400 shares of common stock on August 17, 2026.
A Statement of Changes in Beneficial Ownership was filed on August 19, 2026, disclosing that Albert M Campbell III, a director of National Healthcare Properties, Inc. (NASDAQ:NHP), acquired 4,693 restricted shares of common stock at no cost on August 17, 2026.
Howard G. Welgus, a director of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), filed a Form 4 on August 19, 2026, disclosing stock option exercises and a sale of common stock on August 17, 2026, executed under a pre-established 10b5-1 trading plan.
Please wait processing your request...